Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Apartment Investment and Management Co (AIV) vs Alnylam Pharmaceuticals, Inc. (ALNY) Price & Performance

Apartment Investment and Management CoTrade
Alnylam Pharmaceuticals, Inc.Trade

Price performance (Past 24H)

Key statistics

Apartment Investment and Management Co vs Alnylam Pharmaceuticals, Inc. — how do they compare? Apartment Investment and Management Co trades at $2.62 (market cap $376.16M), while Alnylam Pharmaceuticals, Inc. trades at $223.75 (market cap $29.60B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 78.7× Apartment Investment and Management Co's market cap. Which is the better fit depends on your goals.

AIVALNY
Market Cap
$376.16M$29.60B
Sector
Real EstateHealth
52-Week High
$7.93$491.22
52-Week Low
$2.59$205.48
Enterprise Value
$738.32M$27.56B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Apartment Investment and Management Co

AIV trades at $2.605, down 0.57% today, with a bearish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q1 and Q4 2025 but missing in Q2 and Q3. Despite a net income margin of 400.05% in 2025, revenue declined to $138.49M from $209M in 2024. Analyst consensus shows 1 Buy and 2 Hold ratings, indicating cautious optimism. A dividend of $1.30 is scheduled for H1-2026.

Outlook: AIV's high profitability metrics and undervalued P/B ratio of 0.76 present potential upside, but declining revenue and bearish technicals pose risks. Investment opportunity lies in dividend yield and earnings recovery, while key risks include revenue volatility and competitive pressures in real estate.

Alnylam Pharmaceuticals, Inc.

ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.

The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.

Returns comparison

Trailing returns across standard periods

About Apartment Investment and Management Co

Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment

Read more on AIV

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY